Montelukast for kidney, heart, and eye health in type 2 diabetes
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if montelukast, a common asthma medicine, can help protect the kidneys, heart, and eyes in people with type 2 diabetes. It is for those who already have some kidney damage (stage 2-3) and are taking certain blood pressure or diabetes medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes
- Your kidney function is moderately reduced (stage 2-3) with protein in your urine
- Your blood pressure is under 140/90 mmHg
- Your BMI is 40 or lower
- You are taking an ACE inhibitor or ARB for at least 4 weeks
- You do not have type 1 diabetes, uncontrolled high blood pressure, or very high blood sugar
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether montelukast, a medicine commonly used for allergies, can improve kidney health and blood vessel function in adults with long-term type 1 diabetes. You may join a treatment group and have kidney and circulation measurements taken over the study period.
This trial tests if montelukast, a common asthma medication, can help protect the kidneys and heart in adolescents and young adults with type 2 diabetes. It looks at how the drug affects markers of kidney function and blood vessel health over time.
This trial tests if a drug called formoterol (usually used for asthma) can help protect the kidneys in people with type 2 diabetes and early-to-moderate kidney disease. It may offer a new way to slow kidney damage.
This study tests if montelukast, an asthma medicine, can help people with Parkinson's disease. It is for adults who are already taking levodopa and want to see if adding this drug improves their symptoms.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.